Terremoto raises $108M to make an ‘earthquake’ in small molecule spacenews2026-04-15T11:30:35+00:00April 15th, 2026|Endpoints News|
Beeline Medicines emerges as Bristol Myers’ partner for shelved immunology drugsnews2026-04-15T11:00:51+00:00April 15th, 2026|Endpoints News|
Updated: FDA asks for data on Lilly’s Foundayo to assess heart, liver risksnews2026-04-14T17:50:20+00:00April 14th, 2026|Endpoints News|
Replimune looks ahead as repeat CRL speeds the company’s declinenews2026-04-14T17:19:37+00:00April 14th, 2026|Endpoints News|
Revolution Medicines leads latest wave of stock offerings, totaling $1.5Bnews2026-04-14T15:02:35+00:00April 14th, 2026|Endpoints News|
Endpoints biopharma sentiment survey for Q2 2026news2026-04-14T14:54:52+00:00April 14th, 2026|Endpoints News|
Harbinger raises $100M; Astellas to close Seattle sitenews2026-04-14T14:52:35+00:00April 14th, 2026|Endpoints News|
J&J increasingly confident it can manage Stelara cliff, but work remainsnews2026-04-14T14:47:25+00:00April 14th, 2026|Endpoints News|
Eli Lilly to pay up to $300M for cancer biotech CrossBridge Bionews2026-04-14T12:00:51+00:00April 14th, 2026|Endpoints News|
Parker Institute doubles down on cancer vaccines as part of ongoing rebootnews2026-04-14T11:00:49+00:00April 14th, 2026|Endpoints News|
